IRIC discoveries have spurred major advances in understanding the development of cancer and opened the way to the creation of new, more targeted therapeutic solutions. Its publications are a reflection of these accomplishments. They also demonstrate the Institute’s drive and productivity.
Noncoding regions are the main source of targetable tumor-specific antigens.Sci Transl Med 2018-12-05;10(470).
FZD is a Gα-coupled receptor that exhibits the functional hallmarks of prototypical GPCRs.Sci Signal 2018-12-04;11(559).
Functional selectivity profiling of the angiotensin II type 1 receptor using pathway-wide BRET signaling sensors.Sci Signal 2018-12-04;11(559).
PP2A-B55 promotes nuclear envelope reformation after mitosis in .J. Cell Biol. 2018-12-03;217(12):4106-4123.
Evidence for a role of spindle matrix formation in cell cycle progression by antibody perturbation.PLoS ONE 2018-11-28;13(11):e0208022.
Dynamic phosphoproteomics uncovers signaling pathways modulated by anti-neoplastic sphingolipid analogs.Mol. Cell Proteomics 2018-11-27.
Targeting EIF4E signaling with ribavirin in infant acute lymphoblastic leukemia.Oncogene 2018-11-26.
The BioGRID interaction database: 2019 update.Nucleic Acids Res. 2018-11-24.
The Impact of Post-transcriptional Control: Better Living Through RNA Regulons.Front Genet 2018-11-05;9:512.